Brief: China Biotech Services Sees Net Loss Attributable Of HK$14 Mln For Q1
28/04/2023 11:44
April 28 (Reuters) - China Biotech Services Holdings Ltd
8037.HK :
* SEES NET LOSS ATTRIBUTABLE OF APPROXIMATELY HK$14 MILLION
FOR
2023 Q1 PERIOD
* EXPECTED RESULT DUE TO DECLINES IN DEMAND FOR GROUP'S
COVID-19
NUCLEIC ACID TESTING SERVICES, AMONG OTHERS
Source text for Eikon: ID:nHKS7x6BfN
Further company coverage: 8037.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Biotech Services Holdings
See all newsBrief: China Biotech Services Enters Cooperation Agreement
Brief: China Biotech Services Says HY Revenue From Cont Ops Hk$37.23 Million
Brief: China Biotech Services Expects HY Net Profit Of Not Less Than HK$15.0 MLN
Brief: China Biotech Services Enters Master Collaboration Agreement With Stella Pharma
Brief: China Biotech Services Says BGI Songhe Advances RMB30 Million Loan To Pengbo (Hainan)